UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

Clinical pharmacokinetics, 2018-06, Vol.57 (6), p.647-661

2018

Volltextzugriff (PDF)

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”

Clinical pharmacokinetics, 2023-11, Vol.62 (11), p.1651-1653

2023

Volltextzugriff (PDF)

Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat

CPT: pharmacometrics and systems pharmacology, 2024-01, Vol.13 (1), p.79-92

2024

Volltextzugriff (PDF)

Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study

Clinical and translational science, 2022-05, Vol.15 (5), p.1204-1214

2022

Volltextzugriff (PDF)

Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics

AAPS open, 2022-11, Vol.8 (1), p.1-14, Article 16

2022

Volltextzugriff (PDF)

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S5-S14

2016

Volltextzugriff (PDF)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary circulation, 2019-04, Vol.9 (2), p.1-10

2019

Volltextzugriff (PDF)

Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers

Clinical pharmacokinetics, 2021-03, Vol.60 (3), p.337-351

2021

Volltextzugriff (PDF)

Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults

Clinical pharmacokinetics, 2023-02, Vol.62 (2), p.321-333

2023

Volltextzugriff (PDF)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

European journal of clinical pharmacology, 2021-04, Vol.77 (4), p.527-537

2021

Volltextzugriff (PDF)

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies

Clinical pharmacokinetics, 2020-11, Vol.59 (11), p.1407-1418

2020

Volltextzugriff (PDF)

Comment on: Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults/Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults"

Clinical pharmacokinetics, 2023-11, Vol.62 (11), p.1649-1653

2023

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Clinical pharmacokinetics, 2021-11, Vol.60 (11), p.1407-1421

2021

Volltextzugriff (PDF)

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches

Clinical pharmacokinetics, 2023-11, Vol.62 (11), p.1639-1648

2023

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

Clinical pharmacokinetics, 2024-06, Vol.63 (6), p.751-771

2024

Volltextzugriff (PDF)

Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis

Clinical pharmacology and therapeutics, 2022-11, Vol.112 (5), p.1061-1069

2022

Volltextzugriff (PDF)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban

Clinical pharmacokinetics, 2014-01, Vol.53 (1), p.89-102

2014

Volltextzugriff (PDF)

Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023-03, Vol.23 (2), p.145-155

2023

Volltextzugriff (PDF)

Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs

European journal of pharmaceutics and biopharmaceutics, 2010-09, Vol.76 (1), p.83-94

2010

Volltextzugriff (PDF)

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Clinical pharmacokinetics, 2016-05, Vol.55 (5), p.615-624

2016

Volltextzugriff (PDF)

A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks

Frontiers in physiology, 2011-01, Vol.2, p.4

2011

Volltextzugriff (PDF)

Population Pharmacokinetics and the Pharmacokinetic/Pharmacodynamic Relationship of Riociguat in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S86-S96

2016

Volltextzugriff (PDF)

EXPRESS: Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary circulation, 2019-04, p.2045894019848644

2019

Volltextzugriff (PDF)

Population Pharmacokinetics of Single-Dose Riociguat in Patients with Renal or Hepatic Impairment

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S75-S85

2016

Volltextzugriff (PDF)

Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S58-S65

2016

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”

Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat

Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study

Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers

Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban

Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes

Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks

Population Pharmacokinetics and the Pharmacokinetic/Pharmacodynamic Relationship of Riociguat in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

EXPRESS: Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Population Pharmacokinetics of Single-Dose Riociguat in Patients with Renal or Hepatic Impairment

Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Suchergebnisse filtern